Risk Factors for Clozapine Discontinuation Among 805 Patients in the VA Hospital System

REFERENCES

• Kane J, Honingfeld G, Singer J, Meltzer M: The Clozaril Col-laborative Study Group: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpro-mazine. Arch Gen Psychiatry 1988; 45:789–796
   PubMed Web of Science ®Google Scholar
• Krupp P, Barnes P: Clozapine associated agranulocytosis: Risk and etiology. Br J Psychiatry 1992; 160:38–40
   Web of Science ®Google Scholar
• Abt K, Gulich P, Krupp P, Reinberg W: HLA-Associations in Leponex®/Clozaril ® (clozapine)-induced granulocytopenia and agranulocytosis. Drug Safety 1992; 7 (Suppl 1):10–16
   Google Scholar
• Meltzer HY: Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizo Bull 1992; 18: 515–542
   PubMed Web of Science ®Google Scholar
• Rascati KL, Rascati EL: Use of clozapine in Texas state men-tal health facilities. Am J Hosp Pharm 1993; 50:1663–1666
   Google Scholar
• Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B: Update on the clinical efficacy and side effects of clozap-ine. Schizo Bull 1991; 17:247–261
   PubMed Web of Science ®Google Scholar
• Adams SG, Howe, JT: Predicting medication compliance in a psychotic population. J Nerv Ment Disorders 1993; 181:558–560
   PubMed Web of Science ®Google Scholar
• Pristach CA, Smith CM: Medication compliance and sub-stance abuse among schizophrenic patients. Hosp Commun Psychiatry 1990; 41:1345–1348
   PubMedGoogle Scholar
• Drake RE, Osher FC, Wallach MA: Alcohol use and abuse in schizophrenia: A prospective community study. J Nerv Ment Dis 1989; 177:408–414
   PubMed Web of Science ®Google Scholar
• Buckley PB, Thompson P, Way L, Meltzer HY: Substance abuse among patients with treatment resistant schizophrenia: Characteristics and implications for clozapine therapy. Am J Psychiatry 1994; 151:385–389
   PubMed Web of Science ®Google Scholar
• Hosmer DW, Lemeshow S: Applied Logistic Regression. New York: Wiley; 1989:68–106
   Google Scholar
• Sigola LB, Mufunda J, Adewuyi JO, Keogh E: Factor VII, antithrombin III, leukocyte and platelet counts in a sample of black and white Zimbabwean blood donors. Thrombos Res 1994; 75:73–79
   Google Scholar
• Cora LE, Werley B, Smith A, Chin N, Garde D: Comparison of employees' white blood cell counts in a petrochemical plant by worksite and race. J Natl Med Assoc 1994; 86:620–623
   Google Scholar
• Bao W, Dalferes ER, Srinivasan SR, Webber L, Berenson GS: Normative distribution of complete blood count from early childhood through adolescence: The Bogalusa heart study. Prey Med 1993; 22:825–837
   PubMed Web of Science ®Google Scholar
• Page W, Kuntz AJ: Racial and socioeconomic factors in cancer survival: A comparison of Veterans Administration results with selected studies. Cancer 1980; 45:1029–1040
   PubMed Web of Science ®Google Scholar
• Weinstock MA: Nonmelanoma skin cancer mortality in the United States, 1969 through 1988. Archi Dermatol 1993; 129:1286–1290
   Google Scholar
• Whittle J, Conigliaro J, Good CB, Lofgren RP: Racial dif-ferences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med 1993; 329:621–627
   PubMedGoogle Scholar
• Akerley III WL, Moritz TE, Ryan LS, Henderson WG, Zacharski LR: Racial comparison of outcomes of male de-partment of veterans affairs patients with lung and colon can-cer. Arch Intern Med 1993; 153:1681–1688
   Google Scholar
• Goldberg KC, Hartz AJ, Jacobsen SJ, Krakauer H, Rimm AA: Racial and community factors influencing coronary ar-tery bypass graft surgery rates for all 1986 Medicare patients. JAMA 1992; 267:1473–1477
   PubMed Web of Science ®Google Scholar
• Wenneker MB, Epstein AM: Racial inequalities in the use of procedures for patients with ischemic heart disease in Mas-sachusetts. JAMA 1989; 261:253–257
   PubMed Web of Science ®Google Scholar
• Moore RD, Stanton D, Gopalan R, Chaisson RE; Racial differences in the use of drug therapy for HIV-disease in an urban community. N Engl J Med 1994; 330:763–768
   PubMed Web of Science ®Google Scholar
• Oddone EZ, Horner RD, Monger ME, Matchar DB: Racial variations in rates of carotid angiography and endarterectomy in patients with stroke and transient ischemic attack. Arch Intern Med 1993; 153:2781–2786
   PubMedGoogle Scholar
• Allebeck P, Borje W: Mortality in schizophrenia: A ten year follow-up based on the Stockholm county inpatient register. Arch Gen Psychiatry 1986; 43:650–653
   PubMedGoogle Scholar
• Bruce ML, Leaf PJ, Rozal GPM, Florio L, Hoff RA: Psychiatric status and 9 year mortality data in the New Haven epidemiologic catchment area. Am J Psychiatry 1994; 151:716–721
   PubMed Web of Science ®Google Scholar
• Black DW, Fisher R: Mortality in DSM-IIIR schizophrenia. Schizo Res 1992; 7:109–116
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with al-cohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264:2511–2518
   Google Scholar
• Shaner A, Khalsa ME, Roberts L, Wilkins J, Anglin D, Hsieh SC: Unrecognized cocaine use among schizophrenic patients. Am J Psychiatry 1993; 150:758–762
   PubMed Web of Science ®Google Scholar